Extended Data Fig. 4: Neutralising titres WT SARS-CoV-2 and VOCs in patients treated with anti-CD20. | Nature Cancer

Extended Data Fig. 4: Neutralising titres WT SARS-CoV-2 and VOCs in patients treated with anti-CD20.

From: Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Extended Data Fig. 4: Neutralising titres WT SARS-CoV-2 and VOCs in patients treated with anti-CD20.

Comparison of neutralising titres against WT SARS-CoV-2, Alpha, Beta, and Delta in haematological patients treated with anti-CD20. Boxes indicate the 25 and 75 percentiles, line indicates the median, and whiskers indicate 1.5 times the IQR percentiles. Dots represent individual samples. Dots represent individual patient samples. Dotted lines indicate the lower and upper limit of detection. Significance was tested by two-sided Wilcoxon-Mann-Whitney U test, p < 0.05 was considered significant.

Source data

Back to article page